Every 8-K that PURE BIOSCIENCE (PURE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PURE filings page.
PURE Bioscience reported modestly higher sales but continuing losses for its fiscal third quarter ended April 30, 2026. Net product sales were $506,000, up slightly from $489,000 a year earlier, while net loss widened to $624,000 from $580,000, with loss per share steady at ($0.01).
For the first nine months of fiscal 2026, net product sales rose to $1,656,000 from $1,435,000, and net loss improved to $1,873,000 from $2,067,000. At April 30, 2026, cash and cash equivalents were $983,000 and total liabilities were $7,397,000, including significant convertible notes to related parties, resulting in a stockholders’ deficiency of $5,839,000.
The company highlighted growing adoption of products such as PURE® Clean and its transportation and dairy programs, supported by distribution partners. PURE also announced a leadership transition: CEO Robert Bartlett plans to retire effective July 31, 2026, remaining on the board and as advisor, while President Jeff Kitchell will become CEO and a director on August 1, 2026. Director Bernard Blotner will leave the board to focus on his health.
PURE Bioscience, Inc. entered into a private placement financing on April 30, 2026, raising $1.0 million by issuing 18,131,096 shares of common stock at $0.0553 per share to accredited investors. Board members Tom Y. Lee and Ivan Chen invested approximately $700,000 and $27,650, respectively, with disinterested directors approving the transaction.
The company expects net proceeds of about $1.0 million, which it plans to use for general corporate purposes, including research and development, administrative expenses, and working capital. The unregistered offering relied on exemptions under Section 4(a)(2) and Rule 506 of Regulation D, with investors representing accredited status.
PURE Bioscience, Inc. reported fiscal second quarter 2026 results, showing modest growth with continued losses. Net product sales for the quarter rose to $443,000 from $391,000 a year earlier, while net loss was roughly flat at $785,000 versus $798,000.
For the six months ended January 31, 2026, net product sales increased to $1,150,000 from $946,000, and net loss improved to $1,249,000 from $1,487,000, helped by lower selling, general and administrative costs. Net loss per share remained at $(0.01) for both periods.
The balance sheet shows limited liquidity, with cash and cash equivalents of $198,000 and restricted cash of $75,000 at January 31, 2026, against total liabilities of $7,061,000 and a stockholders’ deficiency of $6,273,000. Common shares issued and outstanding were 111,886,473.
Operationally, PURE obtained USDA Biobased Product Certification for its new product PURE Clean and expects to launch it and fulfill pre-orders in the fiscal third quarter. The company is expanding applications in dairy plants, transportation, and exploring biomedical opportunities through partners, aiming to grow recurring revenue from its SDC-based antimicrobial technology.
Pure Bioscience, Inc. reported the results of its annual stockholder meeting held on February 17, 2026. Shareholders representing 65.97% of the 111,886,485 outstanding common shares were present in person or by proxy.
All seven director nominees were elected, each receiving more than 96% of votes cast. Stockholders also ratified Weinberg & Company, P.A. as independent auditor for the fiscal year ending July 31, 2026, with 99.81% of votes cast in favor.
On an advisory basis, stockholders approved executive compensation with 96.68% of votes cast in favor. They also approved an amendment to the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 250,000,000 shares, supported by 63.87% of outstanding common shares.
PURE Bioscience, Inc. filed a current report to notify investors that it has issued a press release announcing financial results for its fiscal first quarter ended October 31, 2025. The press release, dated December 15, 2025, is included as Exhibit 99.1 and contains details about the company’s operations and financial condition for that period.
The company explains that this information is being furnished rather than filed, so it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC documents.
PURE Bioscience, Inc. announced a leadership change in its executive team. Jeffrey Kitchell has been appointed as the company’s President, effective November 17, 2025, while continuing in his existing role as Corporate Secretary. Robert Bartlett remains Chief Executive Officer, principal executive officer, and a member of the board, but no longer holds the President title.
Kitchell, age 55, has been Vice President of Operations since April 2023 and has served as Corporate Secretary since 2019. He has been with the company since 2001 in a variety of roles overseeing day-to-day operations, legal affairs, and intellectual property, and holds a Bachelor’s degree in Business Administration from the University of Phoenix. His compensation terms are expected to follow the company’s standard officer indemnification and benefit programs, with no new special arrangements or related-party relationships disclosed.
PURE Bioscience (PURE) furnished an 8‑K under Item 2.02 announcing a press release with financial results for the fiscal year ended July 31, 2025. The press release is attached as Exhibit 99.1. The company states the information is being furnished, not filed, and will not be incorporated by reference into other SEC filings.